

Treatment received	Number of patients experiencing SEs	Number of patients under treatment	% of patients under treatment experiencing at least one SE	% of patients under treatment experiencing at least one SE relative to the total number of SEs	mean time to SE occurrence \pm SD (months)
Systemic GCS	46	141	32.62	31.08	11.48 \pm 18.86
injected GCS	19	36	52.78	12.84	6.05 \pm 14.42
Antimetabolites	15	73	20.55	10.14	18.86 \pm 27.39
Anti-TNF	3	28	10.71	2.03	11.00 \pm 11.36
Ciclosporin	21	42	50	14.19	14.29 \pm 12.18
Interferon	37	57	64.91	25	29.81 \pm 17.44
Tocilizumab	4	19	21.05	2.7	14.00 \pm 9.38

Table 5: Number of patients experiencing side effects (SEs) leading to a dose reduction, treatment discontinuation or surgery according to the treatment type.